Novavax, Inc. (NVAX) Stock Price, News & Quote

NVAX Stock Price

For anyone interested in the latest updates and insights related to NVAX stock price and news, FintechZoom provides a comprehensive platform that offers real-time information and analysis.

Stock Overview

This “Stock Overview” table offers a snapshot of a company’s performance.

Price: This is the current market value, telling you how much one share costs.

Change: This shows how much the price moved compared to yesterday, green for up, red for down.

Volume: This tells you how many shares were traded, suggesting activity and investor interest.

High/Low/Open: These show the price range during the day and where it started (open) and finished (close).

Previous Close: This is yesterday’s closing price, providing context for today’s change.

52-Week High/Low: These tell you the stock’s peak and valley over the past year, helping assess current price relative to its broader trend.

NVAX Stock News

NVAX Stock Prices Change

History of Novavax, Inc.

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Here’s a brief history of the company:

Early years (1987-2019):

• Founded in 1987 by Robert Teasdall and Randal Chase.
• Initially focused on developing vaccines for diseases like Ebola and Zika.
• Acquired the Matrix-M adjuvant platform in 2013, which would become a key component of its future vaccines.

Rise during the COVID-19 pandemic (2020-2021):

• Pivots to focus on developing a COVID-19 vaccine, NVX-CoV2373, upon the pandemic’s outbreak.
• Secures funding from CEPI and Gavi, the Vaccine Alliance, to accelerate vaccine development.
• NVX-CoV2373 receives Emergency Use Authorization (EUA) in Indonesia in November 2021, making it the first protein-based COVID-19 vaccine to be authorized for use.

Challenges and setbacks (2022-present):

• Faces manufacturing and supply chain issues, delaying its rollout in other countries.
• NVX-CoV2373 encounters lower vaccine uptake compared to mRNA-based vaccines due to public perception and limited marketing.
• Stock price plummets as the company struggles to meet financial expectations.

Current state and future outlook:

• Despite the challenges, Novavax remains committed to its NVX-CoV2373 vaccine and is working to expand its reach in low- and middle-income countries.
• The company is also developing vaccines for other infectious diseases, including influenza and RSV.
• Novavax’s future success will depend on its ability to overcome manufacturing and supply chain challenges, build trust in its vaccine, and diversify its product portfolio.

Here are some key milestones in Novavax’s history:

• 1987: Founded by Robert Teasdall and Randal Chase.

• 2013: Acquires the Matrix-M adjuvant platform.

• 2020: Pivots to focus on developing a COVID-19 vaccine.

• 2021: Receives EUA for NVX-CoV2373 in Indonesia.

• 2022: Faces manufacturing and supply chain issues, stock price plummets.

• 2023: Continues to work on expanding reach of NVX-CoV2373 and developing new vaccines.

Novavax is a company with a long history of developing vaccines for serious infectious diseases. Despite the challenges it has faced in recent years, it remains a promising player in the global vaccine market. The company’s future success will depend on its ability to overcome its current challenges and execute on its ambitious plans for the future.

Officers and Directors

NVAX Stock Price History

NVAX Stock Reddit

[wp-rss-aggregator feeds=”NVAX”]